Premium
Managing hepatitis C in patients with the complications of cirrhosis
Author(s) -
Mücke Marcus M.,
Mücke Victoria T.,
Lange Christian M.,
Zeuzem Stefan
Publication year - 2018
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.13636
Subject(s) - medicine , hepatocellular carcinoma , cirrhosis , decompensation , hepatitis c virus , hepatitis c , population , gastroenterology , intensive care medicine , virus , immunology , environmental health
Direct acting antivirals ( DAA ) have revolutionized the treatment of hepatitis C virus ( HCV ). Sustained virological response rates of nearly 100% have become common in the general population. However, physicians face the growing problem of managing HCV in patients with the complications of cirrhosis, eg hepatic decompensation or hepatocellular carcinoma ( HCC ). Safety and efficacy remain a clinical challenge in these difficult‐to‐treat patients. This review focuses on the current state of knowledge and treatment regimens in patients with decompensated cirrhosis as well as the potential risk of the development of HCC following DAA therapy.